The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine

Neuroscience

Volumn 155, Issue 3, 2008, Pages 597-602

  Marquez, P ^a   Borse, J ^a   Nguyen, A T ^a   Hamid, A ^a,b   Lutfy, K ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

buprenorphine; conditioned place preference; knockout mouse; morphine; motor activity; ORL1 receptor

Indexed keywords

BUPRENORPHINE; MORPHINE SULFATE; OPIATE RECEPTOR; OPIATE RECEPTOR LIKE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; GENOTYPE; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REWARD;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BUPRENORPHINE; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHINE; MOTOR ACTIVITY; NARCOTICS; PROTEIN BINDING; PSYCHOMOTOR PERFORMANCE; RECEPTORS, OPIOID; REWARD; TIME FACTORS;

EID: 49249098487     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.06.027     Document Type: Article

References (43)

1. Bardo M.T., and Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology (Berl) 153 (2000) 31-43
2. Bloms-Funke P., Gillen C., Schuettler A.J., and Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21 (2000) 1141-1146
3. Ciccocioppo R., Angeletti S., Sanna P.P., Weiss F., and Massi M. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol 404 (2000) 153-159
4. Ciccocioppo R., Economidou D., Rimondini R., Sommer W., Massi M., and Heilig M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 61 (2007) 4-12
5. Di Chiara G., and Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244 (1988) 1067-1080
6. Di Giannuario A., Pieretti S., Catalani A., and Loizzo A. Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats. Neurosci Lett 272 (1999) 183-186
7. Finco G., Polati E., Gottin L., Bartoloni A., Milan B., Zanoni L., and Valle L. Intravenous patient-controlled analgesia (PCA) in the treatment of postoperative pain: rationale and clinical application. Chir Ital 47 (1995) 20-25
8. Fudala P.J., Jaffe J.H., Dax E.M., and Johnson R.E. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 47 (1990) 525-534
9. Greenwald M.K., Johanson C.E., and Schuster C.R. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 56 (1999) 191-203
10. Hawkinson J.E., Acosta-Burruel M., and Espitia S.A. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol 389 (2000) 107-114
11. Heit H.A., and Gourlay D.L. Office-based treatment of opiate addiction. N Engl J Med 349 (2003) 2567-2568
12. Hou Y., Tan Y., Belcheva M.M., Clark A.L., Zahm D.S., and Coscia C.J. Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling. Brain Res Dev Brain Res 151 (2004) 149-157
13. Huang P., Kehner G.B., Cowan A., and Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297 (2001) 688-695
14. Jasinski D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35 (1978) 501-516
15. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., and Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40 (1995) 17-25
16. Johnson R.E., Strain E.C., and Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 70 (2003) S59-S77
17. Kamei J., Saitoh A., Suzuki T., Misawa M., Nagase H., and Kasuya Y. Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci 56 (1995) L285-L290
18. Kamei J., Sodeyama M., Tsuda M., Suzuki T., and Nagase H. Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice. Life Sci 60 (1997) PL333-PL337
19. Kuhlman Jr. J.J., Levine B., Johnson R.E., Fudala P.J., and Cone E.J. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93 (1998) 549-559
20. Lutfy K., Eitan S., Bryant C.D., Yang Y.C., Saliminejad N., Walwyn W., Kieffer B.L., Takeshima H., Carroll F.I., Maidment N.T., and Evans C.J. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23 (2003) 10331-10337
21. Mamiya T., Noda Y., Nishi M., Takeshima H., and Nabeshima T. Nociceptin system plays a role in the memory retention: involvement of naloxone benzoylhydrazone binding sites. Neuroreport 10 (1999) 1171-1175
22. Marquez P., Baliram R., Gajawada N., Friedman T.C., and Lutfy K. Differential involvement of enkephalins in analgesic tolerance, locomotor sensitization, and conditioned place preference induced by morphine. Behav Neurosci 120 (2006) 10-15
23. Marquez P., Baliram R., Kieffer B.L., and Lutfy K. The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 52 (2007) 1336-1341
24. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197 (1976) 517-532
25. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., and Monsarrat B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
26. Mogil J.S., and Pasternak G.W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53 (2001) 381-415
27. Murphy N.P., Lam H.A., Chen Z., Pintar J.E., and Maidment N.T. Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL.1 receptor gene. Brain Res 953 (2002) 276-280
28. Murphy N.P., Lee Y., and Maidment N.T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 832 (1999) 168-170
29. Murphy N.P., Ly H.T., and Maidment N.T. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 75 (1996) 1-4
30. Murphy N.P., and Maidment N.T. Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J Neurochem 73 (1999) 179-186
31. Negus S.S., Bidlack J.M., Mello N.K., Furness M.S., Rice K.C., and Brandt M.R. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 13 (2002) 557-570
32. Negus S.S., Picker M.J., and Dykstra L.A. Kappa antagonist effects of buprenorphine in the rat drug-discrimination procedure. NIDA Res Monogr 95 (1989) 518-519
33. Nishi M., Houtani T., Noda Y., Mamiya T., Sato K., Doi T., Kuno J., Takeshima H., Nukada T., Nabeshima T., Yamashita T., Noda T., and Sugimoto T. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J 16 (1997) 1858-1864
34. Pan Y.X., Bolan E., and Pasternak G.W. Dimerization of morphine and orphanin FQ/nociceptin receptors: generation of a novel opioid receptor subtype. Biochem Biophys Res Commun 297 (2002) 659-663
35. Picard P.R., Tramer M.R., McQuay H.J., and Moore R.A. Analgesic efficacy of peripheral opioids (all except intra-articular): a qualitative systematic review of randomised controlled trials. Pain 72 (1997) 309-318
36. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
37. Richards M.L., and Sadee W. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method. Eur J Pharmacol 114 (1985) 343-353
38. Sadee W., Rosenbaum J.S., and Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 223 (1982) 157-162
39. Sandin J., Georgieva J., Schott P.A., Ogren S.O., and Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci 9 (1997) 194-197
40. Wnendt S., Kruger T., Janocha E., Hildebrandt D., and Englberger W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol 56 (1999) 334-338
41. Yamamoto T., Shono K., and Tanabe S. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J Pharmacol Exp Ther 318 (2006) 206-213
42. Yu T.P., Fein J., Phan T., Evans C.J., and Xie C.W. Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. Hippocampus 7 (1997) 88-94
43. Yuan L., Han Z., Chang J.K., and Han J.S. Accelerated release and production of orphanin FQ in brain of chronic morphine tolerant rats. Brain Res 826 (1999) 330-334